Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours

被引:76
作者
Fleury-Feith, J
Lecomte, C
Renier, A
Matrat, M
Kheuang, L
Abramowski, V
Levy, F
Janin, A
Giovannini, M
Jaurand, MC
机构
[1] Univ Paris 12, INSERM EMI 99 09, Fac Med, F-94010 Creteil, France
[2] Hop Tenon, Serv Histol Biol Tumorale, F-75020 Paris, France
[3] Ctr Hosp Intercommunal, Serv Pathol Professionelles, F-94010 Creteil, France
[4] Fdn Jean Dasset, INSERM U434, CEPH, F-75010 Paris, France
[5] Univ Paris 07, Pathol Lab, ERM 220 INSERM, Hop St Louis, F-75010 Paris, France
[6] Univ Paris 07, ERM 220 INSERM, Pathol Lab, Hop St Louis, F-75010 Paris, France
关键词
asbestos; NF2; mesothelioma; hemizygous mice;
D O I
10.1038/sj.onc.1206593
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biallelic NF2 gene inactivation is frequently found in human malignant mesothelioma. In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in mesothelioma developed in mice presenting a heterozygous mutation of the Nf2 gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres. Asbestos-exposed Nf2(KO3/+) mice developed tumoural ascites and mesothelioma at a higher frequency than their wild-type (WT) counterparts (P<0.05). Six out of seven mesothelioma cell lines established from neoplastic ascitic fluids of Nf2(KO3/+) mice exhibited loss of the WT Nf2 allele and no neurofibromatosis type 2 protein expression was found in these cells. The res its show the importance of the NF2 gene in mesothelial oncogenesis, the potential association of asbestos exposure and tumour suppressor gene inactivation, and suggest that NF2 gene mutation may be a susceptibility factor to asbestos.
引用
收藏
页码:3799 / 3805
页数:7
相关论文
共 45 条
[1]   A trial on the quantitative risk assessment of man-made mineral fibers by the rat intraperitoneal administration assay using the JFM standard fibrous samples [J].
Adachi, S ;
Kawamura, K ;
Takemoto, K .
INDUSTRIAL HEALTH, 2001, 39 (02) :168-174
[2]  
ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230
[3]  
ASPLUND T, 1994, CANCER RES, V54, P4516
[4]   Neurofibromatosis 2 and malignant mesothelioma [J].
Baser, ME ;
De Rienzo, A ;
Altomare, D ;
Balsara, BR ;
Hedrick, NM ;
Gutmann, DH ;
Pitts, LH ;
Jackler, RK ;
Testa, JR .
NEUROLOGY, 2002, 59 (02) :290-291
[5]   HIGH-FREQUENCY OF INACTIVATING MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 GENE (NF2) IN PRIMARY MALIGNANT MESOTHELIOMAS [J].
BIANCHI, AB ;
MITSUNAGA, SI ;
CHENG, JQ ;
KLEIN, WM ;
JHANWAR, SC ;
SEIZINGER, B ;
KLEY, N ;
KLEINSZANTO, AJP ;
TESTA, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (24) :10854-10858
[6]  
CRAIGHEAD JE, 1994, LUNG BIOL HEALTH DIS, V78, P79
[7]  
Cullen RT, 2000, INHAL TOXICOL, V12, P959
[8]  
Cullen RT, 2000, J APPL TOXICOL, V20, P49, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<49::AID-JAT627>3.3.CO
[9]  
2-C
[10]  
DAVIS JMG, 1991, INT J EXP PATHOL, V72, P263